Abstract: Age-related macular degeneration (AMD) is a significant cause of global visual morbidity and is projected to affect 288 million people by the year 2040. The advent of treatment with anti-vascular endothelial growth factor (anti-VEGF) drugs has revolutionized the treatment of neovascular AMD (nAMD) but there have been no similar breakthroughs for the treatment of geographic atrophy (GA) to retard its progression. The advancements in imaging and new understanding of disease mechanisms, based on molecular and genetic models, have paved the way for the development of novel experimental treatment options for GA that aim to cater to a thus far largely unmet need. This review paper focuses on the recent clinical trials of new treatment options for slowing GA progression rates with emphasis on the agents that are currently undergoing, or have already undergone, significant clinical trial testing. Several new groups of drugs, including those targeting the complement cascade and agents considered as neuroprotective, have shown some promising results and could potentially pave the way forward in the treatment of this devastating disease.
A ge-related macular degeneration (AMD) is a significant cause of global visual morbidity, affecting 8.7% of the world's population, and in developed nations is the leading cause of irreversible blindness among the elderly.
1,2 This prevalence is expected to increase due to exponential increases in life expectancy, with 288 million people projected to be affected in 2040.
1 As more than half the world's population resides in Asia, there will be a tremendous increase in the number of people suffering from this condition there, roughly a third of the global prevalence, despite the fact that current prevalence rates are lowest in Asia.
1,3 Early stages of AMD are generally asymptomatic visually with clinical findings of drusen and pigmentary change in the macula but as the disease progresses, central visual impairment results. 4 The advanced stages of the disease present morphologically as 2 entities: geographic atrophy (GA) and neovascular AMD (nAMD) and either form can coexist, 5 likely due to the fact that both forms share common risk factors. 6 The final common pathway for vision loss in both is attributed to photoreceptor dysfunction. 7 In GA this occurs through loss of the retinal pigment epithelium (RPE) with associated loss of the choriocapillaries, whereas in choroidal neovascularization (CNV) there is ingrowth of new vessels from the choriocapillaries under the retinal pigment epithelial layer that extravasate, leading to hemorrhage, exudation, and eventually scarring if untreated. 7 A recent systematic review and meta-analysis of 39 studies on AMD prevalence reported a similar overall prevalence of GA and nAMD, again highlighting the health burden of AMD.
1 The advent of treatment with anti-vascular endothelial growth factor (anti-VEGF) drugs has revolutionized the treatment of CNV but there have been no similar breakthroughs for GA. It is also likely that those eyes rescued from the devastation of nAMD remain at risk of GA. Thus far, there has been no proven treatment for GA, in that there is no known intervention that can slow the growth of areas of GA once developed. However, there is intense activity in this area with the aim to develop treatment options to slow down growth of established areas of GA.
THE ROLE OF IMAGING IN GA
Advances in the development of novel therapeutic options for GA have been limited by a lack of ability to accurately define the area involved and methods to document the progression rate of GA, given that the traditional trial endpoint of visual acuity often remains good until late in the disease process. 8 The surrogate markers used ideally should include both anatomical and functional outcomes to detect and document progression in clinical trials.
8 This can be achieved by using multimodal imaging to anatomically monitor GA progression and microperimetry and low luminance visual acuity to demonstrate functional losses in disease progression. 9 The current recommendation for optimizing the detection and monitoring of atrophy is a multimodal approach, enlisting color fundus photography, confocal fundus autofluorescence, near infrared reflectance, and high-resolution spectral domain or swept source optical coherence tomography volume scans. mechanisms of the retina, where an exacerbated aging response, environmental and genetic risk factors coupled with chronic inflammation and oxidative stress lead to disequilibrium that manifests as disease.
11 Age-related changes include Bruch membrane thickening and RPE dysfunction resulting in deposition of drusen below the RPE and lipofuscin accumulation within the RPE. 12, 13 Advancing age is the strongest known risk factor for AMD 14 and one aspect of biological aging is the accumulation of toxic metabolic byproducts such as reactive oxygen species (ROS).
15
Oxidative stress refers to the cellular damage mediated by ROS, a byproduct of oxygen metabolism. 15 The retina is particularly susceptible to oxidative stress due to its increased metabolic demand and oxygen content, the high levels of photosensitizers and polyunsaturated fatty acids, and continual light exposure. 15 Smoking, an environmental stressor and known risk factor for AMD, simultaneously generates ROS and reduces antioxidant levels, induces hypoxia, and decreases choroidal perfusion, thereby contributing to the development of AMD. 5, 14, 16 The cumulative effect of these changes is thought to activate localized chronic inflammation and tissue destruction, culminating in RPE death and subsequent GA and in some cases is the stimulus for the VEGF-related angiogenesis in nAMD.
17

GENETICS OF AMD
Genetic factors are strongly associated with AMD, with estimates on heritability ranging from 46% to 71%. 18 Over the past 2 decades, much of the genetic associations and related biological pathways have been determined. A major genetic risk factor relates to increased susceptibility to developing immune disequilibrium, specifically affecting the complement pathway, and is thought pivotal to the development of AMD. 19 In 2013, 19 genomic loci associated with AMD risk were reported, 4 of which (CFH, CFI, C3, and C2/CFB) play integral roles in complement cascade regulation, leading to proinflammatory states in individuals at risk. 20 Single nucleotide polymorphisms (SNPs) involved in lipid metabolism, extracellular matrix remodeling, angiogenesis, and apoptosis were also identified although with less robust associations. Genome-wide association studies have also confirmed associations between AMD and variations in the CFH and ARMS2/HTRA1 risk allele, and in some studies the CFH allele preferentially associated with GA risk.
20-22 DICER1 deficiency leading to NLRP3 inflammasome activation has also been implicated in GA. [23] [24] [25] Large consortium studies continue to identify rare alleles associated with AMD, suggesting other potentially important biological pathways.
26 Despite these advances there is still a significant risk that is not accounted for by current genetic risk factors. 27 It is thought that the predictive power of current risk models for AMD is hampered by the paucity of current data on mechanisms other than the common SNPs found with genomic studies thus far. Thus, the clinical role of genetic testing in AMD for determining risk, for diagnosis, or treatment options is currently not determined.
27
The advancements in imaging and new understanding of disease mechanisms based on molecular and genetic models have paved the way for the development of novel experimental treatment options for GA that aim to cater to a thus far largely unmet need. This review paper focuses on the recent clinical trials researching new treatment options for slowing GA progression with emphasis on the agents that are currently undergoing, or have already undergone, significant clinical trial testing.
NEW TREATMENT OPTIONS FOR GA Immune Modulating Agents
Over the past 2 decades, there has been much interest in the role that immune dysfunction, in particular inappropriate complement cascade activation, plays in the etiology of AMD. The complement cascade is divided into 3 entities: the classical pathway, mannose-binding lectin pathway, and the alternative pathway. Each pathway plays a distinct role in immune function by different mechanisms of activation. The 3 pathways converge on a final single pathway via the cleavage of complement factor C3 into C3a and C3b that leads to phagocytosis, inflammation, the formation of a membrane attack complex (MAC), and ultimately cell death. 9 The alternative pathway has been implicated in the pathogenesis of AMD as the majority of risk alleles identified are regulators of the alternative pathway.
12 In addition to the genetic evidence for this pathway, immunohistochemical examination of drusen has implicated complement activation in both the development of drusen and AMD.
28,29 Drusen contain not only lipoprotein and RPE cell remnants but many proinflammatory proteins including apolipoprotein E, coagulation proteins, acute phase proteins, immunoglobulin G, amyloid beta, and complement components and activators.
28-30 Drusen components also activate the NLRP3 inflammasome and, together with other byproducts of oxidative stress, trigger inflammation via multiple pathways. The knowledge of the major role that complement cascade activation plays in AMD has led to several therapeutic options that target the complement cascade.
Eculizumab (Soliris; Alexion Pharmaceuticals Inc, Cheshire, CT) is a systemic complement factor 5 inhibitor designed to prevent MAC formation by inhibiting cleavage of C5 into C5a and C5b.
9 Eculizumab has been used successfully for the treatment of both paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome that are a consequence of complement dysfunction. 31 As such, it was hoped to be a potential treatment for slowing GA progression. However, the COMPLETE study (NCT00935883), a randomized, double-masked phase 2 study, which enrolled 30 patients between November 2009 and March 2011 to receive either intravenous eculizumab or placebo, did not report a significant decrease in GA growth rate. 31 Several factors were postulated to explain this lack of effect, including the small sample size, short duration of study, the possibility that C5 may have been the incorrect target, and that intravitreal drug delivery may have had better ocular penetrance than the systemic mode chosen in this study.
31
Despite these disappointing findings, the MAHALO study showed promising results and supports further work in targeting the complement pathway as a treatment for GA.
32 Lampalizumab (FCFD4514S/anti-factor D; Genentech Inc, San Francisco, CA and F. Hoffmann-La Roche AG, Basel, Switzerland) is an intravitreally administered antigen-binding fragment of a humanized monoclonal antibody targeting complement factor D (CFD).
32
Complement factor D is the rate limiting enzyme in the alternative pathway. 33 Lampalizumab's mechanism of action is by binding to CFD and preventing further activation of the alternative complement pathway. Phase 1 and 2 (MAHALO) lampalizumab trials (NCT00973011; NCT01229215) have shown no ocular or systemic side effects. 32,34 MAHALO was an 18-month, randomized, sham-injection controlled trial conducted between May 2011 and April 2013 that enrolled 129 patients. Patients were randomized 1:2:1:2 to sham monthly, 10 mg lampalizumab monthly, sham every other month, or lampalizumab 10 mg every other month.
The primary outcome measure was the mean change in GA lesion area as measured by autofluorescence from baseline to 18 months. This study reported that monthly intravitreal lampalizumab resulted in a 20% reduction in lesion area progression compared with sham and this effect was noted to be more substantial (44%) in a subgroup analysis of complement factor I (CFI) risk-allele carriers. Phase 3 lampalizumab trials Chroma (NCT02247479) and Spectri (NCT02247531) are currently underway.
Zimura (ARC1905; Ophthotech Corp, Princeton, NJ), an anti-C5 aptamer, is currently undergoing phase 2/3 trials designed to study the effect of monthly intravitreal injections of Zimura versus sham on best corrected visual acuity in patients with nonfoveal GA. The study is expected to end in December 2018 and plans to enroll 300 participants (NCT02686658).
Several other phase 2 studies are ongoing that target other complement factors. APL-2 (AL-78898A; POT-4, Apellis Pharmaceuticals, Crestwood, KY), a C3 inhibitor administered intravitreally, showed no safety concerns in phase 1 trials (NCT000473928) and is now in undergoing phase 2 trials (FIL-LY, NCT 02503332). CLG561 (Novartis International AG, Basel, Switzerland and Alcon Inc, Hünenberg, Switzerland), an inhibitor of properdin, and LFG316 (Novartis International AG, Basel, Switzerland), an anti-C5 agent, are being studied as combination agents in a phase 2 trial (NCT02515942). A more detailed discussion on complement inhibitors is available in a review article by Boyer and colleagues. 9 In addition to the complement inhibitors, several other classes of drugs that target the immune system, either directly or indirectly, have also been trialed as potential therapeutic options for GA.
Corticosteroids have been studied as a potential treatment option for GA due to their anti-inflammatory effects. A randomized phase 2 study to determine the effects of flucinolone acetonide intravitreal inserts on GA growth rates (Iluvien; Alimera Sciences, Alpharetta, GA) has been terminated with results reported as unreliable due to small sample size (NCT00695318).
Sirolimus (Rapamycin; Macusight/Santen, Union City, CA), an immunosuppressive agent that inhibits mTOR (mechanistic target of rapamycin), has also been studied but showed no beneficial effect in a pilot study on prevention of GA progression when administered subconjunctivally (NCT00766649). 35 As this lack of effect was postulated to be due to poor retinal drug delivery, a further study in which sirolimus was administered intravitreally was carried out (NCT01445548). This open-label phase 2 study reported no benefits of treatment either anatomically or functionally. 36 Furthermore, it was noted that 2 of 6 participants had accelerated retinal thinning possibly related to treatment, resulting in suspension of further treatment.
36
Amyloid beta, a component of drusen, is a potent complement activator. Thus, targeting amyloid beta may be a strategy to prevent or slow GA. Several trials have investigated this and the results of the phase 2 trials of an intravenous antibody targeting amyloid beta (GSK933776; GlaxoSmithKline, Brentford, UK)
have not yet been published (NCT01342926). A trial investigating a similar agent, RN6G (Pfizer Inc, NY), has been terminated due to an organizational decision and no results are available (NCT01577381).
Neuroprotective Agents
Geographic atrophy occurs as the final result of RPE and photoreceptor death. Neuroprotective agents offer a possible benefit in GA as they are designed to prevent retinal ganglion cell apoptosis.
Ciliary neurotrophic factor (CNTF) has demonstrated robust neuroprotective effects on photoreceptors and stimulates axonal regeneration. 37 It is administered intravitreally via encapsulated cell technology (ECT) where cells that secrete CNTF are encapsulated in a semipermeable polymer capsule, a specially designed implant (NT-501), to enable reliable sustained drug delivery locally without systemic side effects. 38 A phase 1 trial of intraocular implants of CNTF in patients with retinitis pigmentosa demonstrated its safety and raised the possibility of its benefit in patients with GA. 39 A randomized double-blind study conducted in 2007 of 51 patients with GA showed that CNTF as administered intravitreally via ECT and the NT-501 implant (Neurotech Pharmacueticals, Cumberland, RI) resulted in a dose-dependent increase in retinal thickness and associated preservation of vision at 12-month follow-up. 40 Pharmacokinetic studies done during removal of the implants demonstrated that at up to 2 years after implantation, the intraocular ECT implant maintained therapeutic levels of CTNF in the vitreous without systemic exposure.
41
Tandospirone (AL-8309B), a 5-HT1a receptor agonist and potent neuroprotective agent, was found to protect the retina from photo-oxidative damage in animal studies when applied topically as a 1.75% ophthalmic solution. 42 These encouraging results paved the way for human trials (GATE, NCT00890097). This large randomized double-blind multicenter trial enrolled 772 patients and was completed in May 2012. Participants were randomized to receive either sham or 1.0% or 1.75% ophthalmic solution of the study drug administered twice daily as an eye drop. However, the study reported no significant reduction in GA growth in either treatment arm when compared with placebo. 43 The authors proposed several reasons for this lack of efficacy, among them poor posterior segment penetration by the topical drug route, the test dose being too low, or the drug not being administered at the optimal stage of the disease. 43 Brimonidine, an alpha-2 adrenergic receptor agonist used for its pressure lowering effects for treatment of glaucoma for many years, has been proven to be neuroprotective in glaucoma-related models. 44 Brimonidine has also been shown to have a neuroprotective effect in other models, including optic neuritis, optic nerve crush injuries, and ocular hypertension. [45] [46] [47] In addition, brimonidine has been demonstrated to be protective via modulating amyloid beta toxicity and this is another proposed mechanism for its neuroprotective effect. 48 The results of these studies suggest that brimonidine may potentially have a similar effect in GA. Initial safety and efficacy phase 2 studies on an intravitreal brimonidine tartrate implant (Allergan, Irvine, CA) have reported slower rates of increase in GA size in eyes with the implant compared with sham (NCT00658619). 49 The study enrolled 119 participants randomized to either sham or 200 or 400 µg of treatment and was completed in June 2010. A larger phase 2 trial of 311 patients is currently underway and expected to end in 2019 (BEACON, NCT02087085). BEACON is a double-blind, sham-control study currently underway with its primary outcome being change in size of GA lesion from baseline to 24 months. Participants are randomized to receive either 400 µg sustained release solid brimonidine tartrate implant administered intravitreally on day 1 then every 3 months through month 21 or sham via needleless applicator.
In recent years, the tetracycline antibiotic derivatives minocycline 50 and doxycycline 51, 52 have been found to be neuroprotective in models of neurodegenerative disease. In addition, minocycline has also been demonstrated to protect the RPE against oxidative stress 53 and shows immunomodulatory action by inhibiting neuroinflammatory response of microglia.
54 Several ongoing trials are studying the effects of both these antibiotics taken orally in retarding GA lesion growth rate (NCT02564978, NCT01782989).
Visual Cycle Inhibitors
The visual cycle produces several toxic byproducts, among them cytotoxic lipofuscin bis-retinoids that mediate lipofuscin toxicity. 55 In light of this knowledge, it was postulated that inhibiting the visual cycle would thereby assist in slowing down GA rates by reducing the accumulation of toxic byproducts. Fenretinide, a synthetic derivative of vitamin A, inhibits the visual cycle by reducing levels of retinol in serum, indirectly targeting the visual cycle by reducing retinol concentrations in the eye.
56
However, a phase 2 double-blind randomized placebo-controlled trial enlisting 246 patients that compared 2 dosing regimens of oral fenretinide (RT-101, Sirion Therapeutics Inc, Tampa, FL) (100 mg daily, 300 mg daily) with placebo indicated no statistically significant observed treatment effect on GA lesion growth at 24 months despite showing a trend toward slowing GA lesion growth.
Emixustat is a nonretinoid compound that modulates production of visual chromophore by inhibiting RPE-specific 65kDa protein (RPE65), thereby reducing accumulation of toxic bis-retinoids by directly targeting enzymes that regulate the visual cycle. 57 By lieu of its mechanism of action, emixustat is also expected to reduce rod photoreceptor activity as it decreases levels of available rhodopsin. 58 A phase 2 study of 72 subjects assigned to oral emixustat (ACU-4429; Acucela Inc, Seattle, WA) or placebo reported a dose-dependent reversible effect on rod function, supporting further testing to elucidate its role in treatment of GA.
58
Phase 2/3 studies have been completed but no published results are available as of yet (NCT01802866).
Antioxidants
As oxidative stress plays a role in AMD pathogenesis, therapies that feature antioxidants either orally or topically have been the focus of some trials. OT-551 (Othera Pharmaceuticals Inc, Exton, PA), administered topically as an eye drop, exerts an antioxidant effect by terminating free radical reactions in the eye. 59 However, a small open-label phase 2 trial of 10 patients who received topical 0.45% OT-551 once daily for 2 years did not show a detectable effect of the treatment on GA growth, drusen area, or functional outcomes of microperimetry and contrast sensitivity. 59 Finally, there is also great interest in other therapeutic options to slow progression to GA and these are covered in more detail in reviews by other authors. 49, [60] [61] [62] [63] Early stage developments in stem cell research 64 and the development of the bionic eye 65 also hold much promise for the future management of this devastating condition.
FUTURE DIRECTIONS
The ultimate goal would be to identify eyes at greatest risk of progressing to GA and then have interventions that slow progression to complete GA. The tremendous technological advances in imaging modalities and instruments that enable the measurement of retinal function have enabled researchers to search for potential biomarkers that determine risk of progression and then monitor the progression of disease. Several anatomical changes as seen on multimodal imaging have been suggested as features that seem to increase risk of progression, especially to GA. Some of these are the different patterns observed on fundus autofluorescence, 66 intensity of the inner segment ellipsoid band, 67 hyperreflective foci, 68 internal reflectivity of drusen, 69 and changes on optical coherence tomography (subsidence of the outer plexiform layer and inner nuclear layer and a hyporeflective wedge-shaped band within the limits of the outer plexiform layer and increased transmission into the choroid) that have been called nascent GA. 70 These potential anatomical biomarkers along with measures of mesopic and scotopic retinal function will need to be validated and accepted as surrogate endpoints to enable them to be used to assess efficacy of potential interventions that would commence earlier in the disease process before there is irreversible cell death.
CONCLUSIONS
Presently there are still no proven treatments that slow progression of GA once it is established. However, several new groups of drugs, including those targeting the complement cascade and agents considered as neuroprotective, have shown some promising results. Trials of these novel interventions have been conducted in participants with significant areas of GA already present. This is currently the most pragmatic approach to determine efficacy, as the endpoints are well validated and approved by the US Food and Drug Administration. However, it is possible that failure to reach the primary outcomes may be related to the advanced stage of the disease rather than necessarily a lack of action on appropriate targets. Possibly a longer trial might produce positive results but the trials are only conducted over a few years where, potentially, cells destined to die in the short-to medium-term are nonretrievable but those not yet so destined may be protected. Clearly, until there are validated earlier endpoints, trial design requires an area of GA to measure so that rate of growth can be accurately measured.
